Fig. 7From: Comparing the mapping between EQ-5D-5L, EQ-5D-3L and the EORTC-QLQ-C30 in non-small cell lung cancer patientsDistribution of R2 and RMSE for Each of (a) EQ-5D-5L and (b) EQ-5D-3L after Cross Validation Models (50 % Holdout Sample): BB Model. a. R2 EQ-5D-5L. b. RMSE 5 L. c. R2 3 L. d. RMSE 3 LBack to article page